Oncogenic Role of PTPN14 in Pancreatic Cancer Through β‐Catenin/ NF ‐ κB Pathway Activation
IUBMB Life · 2025
DOI: 10.1002/iub.70078 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Danni Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical College of Hangzhou Normal University (Zhejiang Provincial People's Hospital), Hangzhou, China. Hauptthemen laut MEDLINE: beta Catenin, Pancreatic Neoplasms, Protein Tyrosine Phosphatases, Non-Receptor, NF-kappa B. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Health Bureau of Zhejiang Province.
Abstract (Originalsprache)
Pancreatic cancer (PC) is one of the deadliest malignancies due to early metastasis, therapy resistance, and a highly immunosuppressive microenvironment. Although oncogenic mutations such as KRAS and TP53 are well characterized, the role of protein tyrosine phosphatase non‐receptor type 14 (PTPN14)—a Hippo‐pathway regulator implicated in other cancers—remains unclear in PC. PTPN14 expression was analyzed in PC tissues and cell lines using immunohistochemistry and western blotting. Functional effects of PTPN14 knockdown or overexpression on proliferation, apoptosis, migration, and invasion were evaluated in vitro using CCK‐8, flow cytometry, wound healing, and Transwell assays. Molecular mechanisms were explored via western blotting, immunofluorescence, and rescue experiments focusing on β‐catenin and NF‐κB signaling. In vivo, a xenograft mouse model assessed tumor growth, histopathology, apoptosis (TUNEL), Ki67 expression, and serum cytokine levels (ELISA). PTPN14 was markedly upregulated in PC tissues and cell lines. Silencing PTPN14 significantly inhibited cell proliferation, migration, and invasion, while enhancing apoptosis in vitro. Mechanistically, PTPN14 activated β‐catenin and NF‐κB signaling, promoting β‐catenin nuclear translocation and p65 phosphorylation, with increased IL‐6, TNF‐α, and IL‐1β secretion. In vivo, PTPN14 knockdown suppressed xenograft tumor growth, reduced Ki67 expression, enhanced apoptosis, and lowered serum pro‐inflammatory cytokines. PTPN14 drives PC progression by co‐activating β‐catenin and NF‐κB pathways and promoting a pro‐tumor inflammatory milieu. These findings highlight PTPN14 as a promising therapeutic target to inhibit PC aggressiveness and inflammation‐driven tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical College of Hangzhou Normal University (Zhejiang Provincial People's Hospital), Hangzhou, China.
- Center for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
- Research Institute of Anesthesiology and Perioperative Medicine, Hangzhou Medical College, Hangzhou, China.
ORCID-Profile: Jintao Liu
Förderung
- Health Bureau of Zhejiang Province
Zitieren
APA
Luo, D., Luo, X., Qian, S., & Liu, J. (2025). Oncogenic Role of PTPN14 in Pancreatic Cancer Through β‐Catenin/ NF ‐ κB Pathway Activation. IUBMB Life. https://doi.org/10.1002/iub.70078
Vancouver
Luo D, Luo X, Qian S, Liu J. Oncogenic Role of PTPN14 in Pancreatic Cancer Through β‐Catenin/ NF ‐ κB Pathway Activation. IUBMB Life. 2025. doi:10.1002/iub.70078
BibTeX
@article{Luo2025,
author = {Luo, Danni and Luo, Xiaopan and Qian, Shaojie and Liu, Jintao},
title = {Oncogenic Role of PTPN14 in Pancreatic Cancer Through β‐Catenin/ NF ‐ κB Pathway Activation},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70078}
}
EUVIMED